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In vitro sensitivity of clonogenic cells in resisting and relapsing patients
with acute myelogenous leukaemia
J.-P. Marie, R. Zittoun & D. Thevenin
Laboratoire de cinetique et de culture cellulaire, Service d'Hematologie de l'H6tel-Dieu, Paris.
Summary The evolution of in vitro bone marrow clonogenic leukaemic cells (CFU-L) drug sensitivity was
studied in 23 patients with acute myeloid leukaemia treated with anthracycline and cytosine arbinoside (ara-
C). In 12 patients tested before and after first induction treatment failure (interval: 6+4 weeks), the sensitivity
remained stable for daunorubicin and showed little variation for ara-C. Among eleven patients tested before
treatment and at first relapse (interval: 13+7 months), in vitro CFU-L sensitivity revealed no correlation
between the two measurements, and a trend in decreased sensitivity to daunorubicin and ara-C. These
findings suggest that induction failures could be related to factors other than simple selection of a resistant
CFU-L subclone.
In human acute myeloid leukaemia (AML), patients who fail
to respond to first induction treatment as well as relapsing
patients generally have a short life expectancy. It is generally
assumed that this poor prognosis is due in part to chemo-
resistance. Alternate schedules of chemotherapy could over-
come this resistance to conventional therapy, and 50% or
more patients treated after failure of induction treatment
could reach a subsequent remission (Herzig et al., 1983). On
the other hand, a second remission could be obtained in
41% of relapsing patients with a reinduction treatment
identical to the one given for the first remission induction
(Peterson & Bloomfield, 1981).
The selection or the emergence of a leukaemic clone
resistant to chemotherapy is therefore one of the probable
explanations of induction treatment failure and relapse in
acute myeloid leukaemia. The hypothesis of selection of a
resistant subpopulation was commonly observed in experi-
mental systems (Skipper et al., 1978), but was rarely
explored in AML (McCulloch et al., 1981).
The drug sensitivity of clonogenic leukaemic cells (CFU-L)
can be tested by in vitro assays (Preisler, 1980; Marie et al.,
1987), with good in vitro-in vivo correlations, with few
exceptions (McCulloch et al., 1982). We have used a
leukaemic clonogenic assay giving 87% successful leukaemic
growth (Marie et al., 1982; Marie, 1987) to explore
modifications of the in vitro sensitivity of bone marrow
CFU-L to duanorubicin (DNR) and cytosine arabinoside
(ara-C) during evolution of AML in 23 adult patients treated
with conventional doses of ara-C and anthracycline.
Patients and methods
Twelve patients (mean age: 55+11 years old, range: 26-77)
with AML (7 M2, 5 M4; 72.5 + 14% bone marrow leukaemic
cells before treatment) showed resistance to treatment induc-
tion including, in all cases, a combination of anthracycline
(adriamycin or DNR) and ara-C at conventional dose (100
to 200mgm 2 x 7 days) according to 'AML5,6,7,8' protocols
of the European Organization for Research on Treatment of
Cancer (EORTC). Resistance to chemotherapy was docu-
mented 21 days following the end of the induction treatment
by bone marrow aspirate showing 58+20% leukaemic cells.
The interval between the two in vitro studies (before and
after treatment) was 6 weeks+4 (3-18 weeks). Salvage
therapy (anthracycline+ara-C, 2 cases; high doses of ara-C
(HiDAC)+amsacrine, 4 cases; amsacrine+VP16213, 2 cases)
was successful in 3 cases (nos. 6, 9, 10) and failed in the 5
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other patients. Two patients were treated with a phase II
protocol (low dose ara-C or aclacinomycine) without success,
and two patients did not receive subsequent chemotherapy.
Eleven patients (mean age: 55 + 13 years old, range: 22-69)
with AML (2M1, 3 M2, 3 M3 3 M4; 71% + 18 bone marrow
leukaemic cells) were tested at diagnosis and at first relapse.
These patients entered into CR after induction treatment
including anthracycline (adriamycin: 2 cases; DNR: 9 cases)
and ara-C at conventional dose ('AML5,6' of'EORTC). A
consolidation course with the same drugs was administered
in all cases. Maintenance treatment was alternation of
amsacrine+HiDAC/amsacrine+5 azacytidine (6 courses) in 4
cases, DNR+ara-C (6 courses) in 3 cases, 6 mercapto-
purine+methotrexate orally and DNR+VCR ( x 6) in 2 cases,
6 thioguanine+ara-C+immunotherapy in one case, and
HiDAC+amsacrine ('intensive consolidation' x 2) in one case.
Relapse (74+ 16% bone marrow leukaemic cells) occurred
after an average of 13+7 months (range: 5-30 months)
following attainment of CR. Six patients achieved as second
CR with DNR+ara-C (3 cases) or HiDAC+amsacrine (3
cases), 5 patients failed (2 deaths during treatment and 3
resistant cases).
Methods
Cell preparation
Mononuclear cell suspensions were obtained from marrow
aspirate by centrifugation using density 1077MSL (Eurobio
Lab.).
T lymphocytes were depleted by a second centrifugation
after sheep erythrocyte rosette formation as described by
Minden et al. (1979).
CFU-L assay
Blast colony formation. The technique has been described
previously (Marie et al., 1983). Briefly, 2 x 104T-depleted
cells in 0.1 ml alpha medium were plated with methyl
cellulose (0.8%), 20% foetal calf serum (Flow Laboratories)
and 10% PHA-LCM in 1 ml microwells (Titertek Lab.).
Eight to 10 microwells were plated and incubated in a moist
atmosphere with 6% carbon dioxide.
Aggregates >20 cells were counted at day 7 (plating
efficiency 1, or PE1), and several colonies were pooled for
May-Griinwald giemsa staining and detection of T cells if an
unusual aspect of the colonies was noted.
Drug exposure
According to in vivo drug pharmaco-kinetics during AML
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protocols, the cells were exposed briefly to anthracycline and
continuously to ara-C: T-depleted cells (3 x 106) were
incubated in alpha medium containing 10% FCS for 30min
with 10 7, 10 6 and 10 5M daunorubicin (DNR). The cells
were pelleted, washed twice in large alpha medium excess
and plated as before.
For ara-C, continuous exposure to 10-7, 10-6 and 10-5M
were tested, the drug being added just before plating.
A minimum of 4 microwells was counted at day 7 for each
drug. Results were expressed as (i) number of surviving
colonies, percentage of inhibition of CFU-L compared to
controls without drugs (a minimum of 15 colonies per well
in controls was required for results to be recorded); and (ii)
dose inhibiting 50% of the CFU-L for ara-C (DI50) and
70% of the CFU-L for DNR (DI70), according to our
previous data (Marie ct al., 1987).
Statistics
The Mann-Whitney test was used to compare quantitative
data, and linear regression analysis for comparison of results
of replicate studies in each patient.
Results
Resisting patients (Table I)
The cloning elfficiency (PEI) was stable in 7 patients and
decreased in the 4 other cases.
The in vitro CFU-L drug sensitivity showed few variations
when tested before treatment and at time of leukaemic
regrowth: the level of CFU-L inhibition to DNR (30 min
exposure, Figure 1) to 10 6M (55+410o and 56.6+36%
respectively; r=0.8, P=0.006) and to 10 5M (76+ 31 and
79 + 39, -0.98, P=0.005) did not change. A significant
increase (>1 log) in the DI0 (DNR) was observed only in
3/12 patients.
The CFU-L inhibition after continuous exposure to
10 5M ara-C was less stable than for DNR (Figure 2) in
each patient (89+144% at induction and 79+210% at
Ieukaemic regrowth; r=0.57, P=0.06). An increase of DI50
(ara-C) was observed in 3/12 patients.
Four patients were treated with a 'salvage' protocol
including HiDAC and AMSA, and a CR obtained in 3
cases, despite in vitro CFU-L resistance to 10- 5M ara-C
(equivalent to conventional doses) in one case (pt 10).
Relakpsing patient.s (Table II)
The PEI remained stable in 5 patients, increased in 5 and
decreased in one.
The CFU-L drug sensitivity showed variations when we
compared CFU-L inhibition by ara-C and DNR at diagnosis
and at relapse. In the same patient, repeat measurements
failed to correlate (r -0.4 for 10 6M DNR, r=0.3 for
10 5M DNR; r =0.2 for 10 6M ara-C, r=0.4 for 10 5M
ara-C).
CFU-L sensitivity to DNR (Figure 3) remained stable
(3 pts) or decreased (6 pts) in the 9 patients who received
DNR during maintenance treatment; it remained stable in
the 3 other patients who did not. The DI70 to DNR
increased in 4/10 evaluable patients.
The CFU-L inhibition by 10 5M ara-C (Figure 4)
decreased dramatically ( -45 + I 1%) in 5 patients despite the
absence of ara-C in the maintenance regimen in 2 of them; it
remained stable in 3 patients and increased in 2 patients,
although all these 5 patients received ara-C during their
remission. The DI50 for this drug increased in 5/11 patients.
The trecatment of relapse was successful using DNR +ara-C
or HiDAra-C+AMSA in 6/11 cases, but only one (no. 20)
had a longer second remission than the first one. Among
patients showing in v,itro CFU-L resistance to at least one
drug at time of relapse, only 2 out of 6 entered into
remission (in one case after HiDAC+AMSA, one after
staindar-d doses ol DNR-ara-C), whereas all the 4 evaluable
patients with CFU-L still sensitive to drug entered into CR.
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Figure 1 Dose response curve of inhibition of clonogenic leuk-
alemic cells by 30 min exposure to 10 a, 10 and 10 M DNR in
'resisting' patients (mean +s.d.).
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Figure 2 Dose response curve of inhibition of clonogenic
leukaemic cells by continuous exposure to 10 ', 10'6 and 10-5M
of ara-C in 'resisting' patients (mean+s.d.).
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Figure 3 Dose response curve of inhibition of clonogenic
leukaemic cells by 30min exposure to 10 7, 10 ' and I) 5M
DNR in 'relapsing' patients (mean+s.d.).
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Table I Two determinations of CFU-L first plating efficiency (PEI), in vitro sensitivity to ara-C and DNR, suicide index, treatment
received and clinical results of these treatments in patients with primary clinical drug resistance.
Drug exposure to
Ara-C DNR 3H thymi-
Pts PEI 10-7M 10-6M 10-5M 10-7M JO-6M 10-5M dine Treatment received
1 21+3 nd 0 0 25+7 25+6 8+2 26+5 TAD=E2
+18
w
2
+5
w
3
+3
w
4
+6
w
+8
w
6
+3
w
7
+6
w
15 +2
(100)
nd 21+4
(0)
15+7 nd
21+4 nd
50 + 3
46+6
62+5
59 + 3
32 + 7
15 + 1
54+ 13
62+12
70+8
47 +9
8 110+ 13
+4 73+14
w
9 40+6
+8 21 +4
w
10 54+1
+4 55+11
w
11 181 +6
+6 48+2
w
12 83+6
+3 19+2
w
(100)
nd
0 0
(100) (100)
nd 5+4
(81)
nd 6+1
(88)
nd 31+1
(33)
24+2 20+2
(61) (68)
20+2 21+2
(66) (64)
nd 0
(100)
5+1 0
(70) (100)
nd nd
51.12
(18)
49+3
(30)
18 +3
(62)
nd
nd
16+4
(60)
3+1
(86)
nd
nd
nd
nd
nd
nd
31 +6
(49)
32+2
(54)
28 + 1
(40)
0
(100)
21+1
(54)
15+5
(76)
18+2
(69)
0
(100)
0
(100)
20+9
(64)
29
(53)
20+ 5
(69)
2+1
(96)
(0)
7+1
(95)
nd
nd
4
21
1:
3'
24
nd 64+12
(41)
nd 25+4
(65)
12+1
(69)
1+5
(95)
nd
nd
nd
nd
nd
nd
8+3
(80)
0
(100)
56+4
(0)
3+10
(40)
50+39
(72)
0
(100)
0
(100)
0
(100)
(0)
nd
nd
nd
1+2 25+3
(17) (49)
8+2 26+6
(39) (43)
2+2 5+2
(80) (92)
7+1 22+12
(39) (64)
6_3 27+6
(20) (15)
16+ 1 16+8
(0) (0)
49 nd
(9)
4+8 3+3
(77) (96)
1+3 21+5
(82) (70)
9+3 35+3
(0) (25)
nd 27+6
(75)
nd 18+2
(75)
14+4
(65)
10+5
(52)
63 +7
(0)
nd
0
(100)
0
(100)
nd
nd
1+1
(99)
0
(100)
45+12
(15)
38+ 10
(31)
0
(100)
15+1
(68)
20+ 1
(76)
6+2
(68)
(63)
nd
nd
nd
19+2
(62)
10+2
(78)
0
(100)
0
(100)
30+2
(8)
15+2
(0)
3
(94)
0
(100)
9+3
(88)
2+1
(96)
(12)
17+1
(0)
Low doses ara-C = no change
nd AML5 =E2
nd AML5 =E3
32+6 TAD=E2
(37)
42 +2 Aclacynomycine =E2
(9)
nd AML6=E1
52+2
(14)
11+5 AML5=El,
(64)
8+6
(46)
nd AML6 =E2
nd HiDAC+Al
TAD=E2
MSA=CR
37+4 AML7=E2
(48)
20+5
(58)
nd 94+20 AML6 =E2
(15)
nd 73+ 14 HiDAC+AMSA=E2
(59)
0
(100)
0
(100)
6+3
(89)
nd
nd AML6 =CR, early relapse
nd HiDAC+AMSA=CR
44+4 AML6 =E2
(17)
47+15 HiDAC+AMSA =CR
(15)
nd 144+7 AML7=E2
(21)
nd 44±6 VP16+AMSA=E2
(10)
nd 49+5 AML8 =E2
(41)
nd 10+2 VP16+AMSA=E2
(49)
w: weeks; PEI: number of colonies/I x 104 cells plated. CFU-L growth after continuous exposure to 10-7, 10-6 and 10-5M of ara-
C or to 30min exposure to 10-7, 10-6 and 10- M of DNR. Percentage of CFU-L inhibition is given in brackets.
Treatments: TAD: 6-thioguanin, 200mgm-2 x 7, ara-C 200mgm-2 x 7, DNR 60mgm -2 x 3; AML5 of EORTC: adriamycin
50mgm-2 x1, vincristin mgm-2, Ara-C 160mgm-2 x 7. AML6,7,8 of EORTC: DNR 45mgm-2 dl-d3 (30mgm-2 in AML7),
vincristin 1.4mgm-2 d2 (AML6,7), ara-C 200mgm-2 dl-d7; HiDAC+AMSA: ara-C I or 2gm-2x 12+AMSA 12Omgm-2x3
VP16+AMSA=VP16: JOOmgm-2 x 5+AMSA 00mgm-2 x 5. El: Complete resistance with persistence ofcirculating leukaemic cells
without aplasia; E2: failure with leukaemic regrowth; E3: prolonged aplasia with leukaemic regrowth; CR: complete remission.SENSITIVITY OF CLONOGENIC CELLS IN AML 573
Table II Two determinations of CFU-L first plating efficiency (PEI), in vitro sensitivity to ara-C and DNR, treatment
received and clinical results of these treatments in patients relapsing after achieving a complete remission.
Drug exposure to
Ara-C DNR
Pts PE 1O-7M 1O-6M 10-5M JO-7M JO-6M 10-SM
13 22+7
+6 29+6
m
14 16+2
+5 82+14
m
15 40+9
+6 53
m
16 66+ 15
+16 73+9
m
17 158+30
+30 72+9
m
18 38+5
+11 46+2
m
19 24+4
+10 114+3
m
20 46+5
+20 92+8
m
21
+14
m
40+ 13
51 +2
22 56+22
+ 10 81 +9
m
23 23+4
+ 17 54+3
m
65 +5
(0)
56+4
(0)
21+2
(5)
28+4
(0)
6+3 3+ 1
(62) (81)
nd 60+1
(27)
42+4
(0)
nd
42+ 10
(36)
27+ 1
(63)
27+4
(82)
31 + 13
(57)
28+4
(26)
39 +2
(15)
nd
121 + 19
(0)
60+6
(0)
42+5
(54)
48+11
(0)
nd
25
(55)
nd
27+2
(31)
47
(11)
16+3
(76)
26+ 6
(64)
18 +5
(89)
38+4
(48)
14+2
(61)
26+6
(44)
13
(46)
57 + 15
(50)
58 + 8
(0)
27 + 3
(71)
19+1
(53)
nd
16
(71)
nd
nd 42+ 14
(0)
nd nd
18+ 7
(18)
19+4
(33)
5+2
(68)
63+ 3
(22)
35 +2
(13)
56
(0)
1+1
(98)
27+ 1
(63)
14+6
(91)
34+2
(53)
12+3
(68)
26+5
(43)
6
(75)
39+2
(66)
27+ 1
(41)
9+6
(90)
12+4
(70)
nd
0
(100)
48+4
(41)
7+3
(69)
48+3
(11)
14+1
(36)
32+4
(0)
5+3
(68)
60+ 13
(27)
0
(100)
18+ 5
(37)
1+1
(94)
59+6
(28)
0
(100)
5+1
(82)
0
(100)
26±4
(68)
0 0 0
(100) (100) (100)
60 40 24
(0) (24) (55)
65+3
(0)
33 +5
(55)
63 +6
(61)
21+6
(71)
25+ 1
(34)
18+6
(61)
nd
95+9
(16)
22+ 1
(52)
23 +3
(75)
55+9
(37)
52+4
(0)
30+9
(54)
25+4
(66)
23+5
(85)
21+5
(71)
0
(100)
31+5
(33)
13
(46)
51+2
(55)
0
(100)
11+3
(88)
29+4
(27)
16+1
(69)
nd 13+2
(22)
82+ 10 43+3
(0) (47)
nd
6+1
(92)
nd
0
(100)
0
(100)
0
(100)
nd
0
(100)
0
(100)
0
(100)
20+5
(50)
1+1
(97)
0
(100)
0
(100)
Treatment received
AML6, AMSA+HiDAC/
AMSA+SAZA
HiDAC+AMSA=E2
AML5, DNR+VCR,
6MP+PU
AMSA+HiDAC=E2
AML6, AMSA+HiDAC/
AMSA+SAZA
AML6=E2
AML6, DNR+Ara-C
AML6=CR
AML5, 6TG+ara-C+
Immunotherapy
AML6 =E4
AML6, DNR+6MP+MTX
HiDAC+AMSA=CR
AML6, AMSA+HiDAC/
AMSA+SAZA
HiDAC+AMSA=E4
AML6, DNR+ara-C
HiDAC+AMSA=CR
AML6, DNR+ara-C
AML6=CR
AML6, HiDAC+AMSA
AML6=CR
nd nd nd AML6, AMSA+HiDAC/
AMSA+5AZA
nd 35+4 nd AML8 =CR
(34)
m: months; PEl: number of colonies/l x 104 cells plated. CFU-L growth after continuous exposure to 10-7, 10-6 and
10-M of ara-C or to 30min exposure to 10-7, 10-6 and 10-5M of DNR. Percentage of CFU-L inhibition is given in
brackets.
Treatments. AML5 of EORTC: adriamycin 50 mgm -2 x 1, vincristin I mgm-2, ara-C 160 mgm-2 x 7; consolidation:
idem, maintenance: either purinethol +6-mercaptopurine +(DNR+vincristin x 9)+androgen or6-thioguanin +ara-C immuno-
therapy. AML6,8 of EORTC: DNR 45mgm-2 dl-d3, vincristin 1.4mgm-2 d2 (AML6), ara-C 200gm-2 dl-d7;
consolidation in AML6: idem but DNR dl only. Maintenance for AML6: 6 courses of either DNR+ara-C or
AMSA+HiDAC/AMSA+SAZA. AMSA+HidDAC: AMSA 120mgm-2 x 5+ara-C 3gm-2 x4. HiDAC+AMSA: ara-C 1
or 2gm-2 X 12+AMSA 120mgm-2 x 3; E2: failure with leukaemic regrowth; E4: toxic death; CR: complete remission.
In our patients, in vitro CFU-L sensitivity to 10-6M DNR
was higher in patients entered into CR (73 +22%) than in
resistant patients (55+41%), but without statistical
significance.
Discussion
Repeated study of CFU-L drug sensitivity in 23 patients
treated for AML showed different results according to the
time of the second study.
In treatment failures, the sensitivity to DNR concen-
trations used for in vitro-in vivo correlations did not change
significantly when tested before and after chemotherapy. In
these resistant patients, the interval between the in vitro
studies was short (6 weeks), a time probably insufficient to
develop a leukaemic clone with properties different than
those observed before therapy. These results confirm the
preliminary report of McCulloch (1982), who have
repeatedly assessed the self renewal capacity and drug
sensitivity of circulating CFU-L: these parameters showed
little variation, except evidence of developing drug resistance
in a few patients (one relapse and one primary resistance).
These data suggested that drug sensitivity and self renewal574 J.-P. MARIE el al.
capacity are heritable characteristics in leukaemic clones, but
the small number of patients (7) does not permit definitive
conclusions.
Treatment failure was predicted by the first in vitro CFU-
L sensitivities to DNR but not to ara-C. This superior
predictive value of DNR sensitivity was also found in a
larger series (Marie et al., 1987).
In patients achieving a complete remission, the emergence
of a leukamic clone with different properties from that
observed at diagnosis was noted at relapse in a majority of
cases: the sensitivity to 10-6M DNR or 1-0 M ara-C
decreased markedly in 5 patients, increased in one and
remained stable in the five others. This can be related to
other modifications observed in the study of leukaemic
populations in relapse viz. additional chromosomal abnor-
malities (Pui et al., 1986), or change in surface phenotype
(Borella et al., 1979; Lauer et al., 1982; Pui et al., 1986; Stass
et al., 1984), suggestive of clonal evolution. Schwarzmeier et
al. (1984), using a short term test with 3H uridine incor-
poration in a whole peripheral blast cell population, also
noted an in vitro acquired drug resistance in 2 patients tested
repeatedly.
The increase of CFU-L drug resistance observed in several
relapsing patients could explain the poor prognosis of AML
patients in relapse. The reduction of leukaemic cells during
induction treatment and the long time between the two in
vitro studies in these patients are in favour of the expansion
of a subclone either existing from the beginning of the
disease, or selected by mutations in the residual leukaemic
clone.
In the great majority of cases, the second CR is shorter
than the first one, like in our present study, reflecting a
relative chemoresistance, with only moderate cytoreduction
during reinduction treatment. Our comparative observations
in resistant and relapsing patients are surprising, if one takes
into account the good correlation normally observed
between in vitro sensitivity of clonogenic cells to DNR+ara-
C and clinical response (Zittoun et al., 1987): one could
expect, on the contrary, the emergence of in vitro resisting
clones after failure of induction treatment and persistence of
sensitive clones in most relapsing patients. This could be
explained either by the inability of our clonogenic assay to
measure leukaemic stem cell properties, or by other resis-
tance mechanisms involving cell kinetic (Raza et al., 1987) or
pharmacological factors (Plunkett et al. 1985). The
properties of more primitive leukaemic stem cells could be
studied in liquid cultures (Nara & McCulloch, 1985), and
could perhaps better account for the clinical evolution of the
disease.
This work was supported in part by grants from 'La Ligue
Franqaise contre le Cancer' and Universite Paris VI.
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